Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy

Susanna Esposito, Jelena Bojanin, Alessandro Porta, Laura Cesati, Laura Gualtieri, Nicola Principi

Research output: Contribution to journalArticlepeer-review

Abstract

This study shows the long term safety of discontinuing secondary prophylaxis for Pneumocystis pneumonia in 5 human immunodeficiency virus-infected children who had recovered from a confirmed episode of Pneumocystis pneumonia, had 15% for ≥3 months during highly active antiretroviral therapy.

Original languageEnglish
Pages (from-to)1117-1120
Number of pages4
JournalPediatric Infectious Disease Journal
Volume24
Issue number12
DOIs
Publication statusPublished - Dec 2005

Keywords

  • Highly active antiretroviral therapy
  • Human immunodeficiency virus infection
  • Opportunistic infections
  • Pneumocystis pneumonia
  • Prophylaxis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy'. Together they form a unique fingerprint.

Cite this